Clinical Trial Update: An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) [Phase 2]

View source ↗

Summary

Open-label Phase 2 study evaluating JSB462 (Luxdegalutamide) in combination with Abiraterone in adult men with metastatic hormone-sensitive prostate cancer; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)
• Luxdegalutamide (JSB462) (luxdegalutamide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Hormone-sensitive Prostate Cancer | Phase 2 | Status: RECRUITING